Research programme: mRNA therapeutics - Arcturus Therapeutics/Ultragenyx Pharmaceutical
Latest Information Update: 21 Mar 2016
At a glance
- Originator Arcturus Therapeutics
- Developer Arcturus Therapeutics; Ultragenyx Pharmaceutical
- Class RNA
- Mechanism of Action RNA inhibitors; RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified